{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-079774","form_type":"8-K","ticker":"RMTI","cik":"0001041024","company_name":"ROCKWELL MEDICAL, INC.","filed_at":"2023-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.987477+00:00","generated_at":"2026-06-13T09:46:05.526384+00:00","sec_items":["1.01","2.02","8.01","3.02","3.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rockwell Medical acquires Evoqua hemodialysis concentrates business for $16M total consideration","bullets":["Acquisition for $11M cash at closing plus two $2.5M installments at 12 and 24 months.","Funded from cash; post-close cash was $15.3M.","Acquired business generated ~$18M trailing revenue and >$3.3M EBITDA.","2023 revenue guidance raised to $82-86M from prior expectation.","Preliminary Q2 2023 revenue $18.0-18.3M, net loss per share pro forma $(1.31) for FY 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-079774","json":"https://secwatch.observer/filing/0001104659-23-079774.json","markdown":"https://secwatch.observer/filing/0001104659-23-079774.md","text":"https://secwatch.observer/filing/0001104659-23-079774.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1041024/000110465923079774/0001104659-23-079774-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1041024/000110465923079774/tm2320979d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T09:46:05.526384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"27400face69bc8ade80f8ffef647bc329a67557d","claim":"ROCKWELL MEDICAL, INC. reported 2023 results: revenue between $82.0 million and $86.0 million. Guidance raised.","evidence_excerpt":"Rockwell Medical increases its 2023 revenue guidance to between $82.0 million and $86.0 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465923079774/0001104659-23-079774-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023"},{"label":"Revenue","value":"between $82.0 million and $86.0 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"731da788586ccd9f776f44ab570c7eaa4aaf6140","claim":"ROCKWELL MEDICAL, INC. entered into Asset Purchase Agreement with Evoqua Water Technologies LLC valued at $11,000,000 in cash paid at Closing and equal annual installments of $2,500,000 (effective 2023-07-10).","evidence_excerpt":"On July 10, 2023, Rockwell Medical, Inc. (the “Company”) executed and consummated the transactions contemplated by an Asset Purchase Agreement (the “Purchase Agreement”) with Evoqua Water Technologies LLC, a Delaware limited liability company (“Evoqua”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465923079774/0001104659-23-079774-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Evoqua Water Technologies LLC"},{"label":"Value","value":"$11,000,000 in cash paid at Closing and equal annual installments of $2,500,000"},{"label":"Effective","value":"2023-07-10"}],"fact_type":"material_agreement"},{"claim_id":"d3c25824b6ea06e9af154d53c2e502a31f71cfb8","claim":"ROCKWELL MEDICAL, INC. entered into Letter Agreement with Armistice Capital Master Fund Ltd. valued at approximately $13.8 million (effective 2023-07-10).","evidence_excerpt":"On July 10, 2023, the Company entered into a letter agreement (the “Letter Agreement”) with Armistice Capital Master Fund Ltd. (“Armistice”), which held a warrant (the “Prior Warrant”) to purchase 9,900,990 shares of common stock of the Company (the “Common Stock”) with an exercise price of $1.39 per share, offering Armistice the opportunity to exercise the Prior Warrant for cash, provided the Prior Warrant was exercised for cash on or prior to 5:00 P.M. Eastern Time on July 10, 2028 (the “End Date”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465923079774/0001104659-23-079774-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Armistice Capital Master Fund Ltd."},{"label":"Value","value":"approximately $13.8 million"},{"label":"Effective","value":"2023-07-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}